Author: Okazaki, Shunichiro; Nagoya, Satoshi; Matsumoto, Hiroshi; Mizuo, Keisuke; Sasaki, Mikito; Watanabe, Satoshi; Yamashita, Toshihiko; Inoue, Hiromasa
                    Title: Development of non-traumatic osteonecrosis of the femoral head requires toll-like receptor 7 and 9 stimulations and is boosted by repression on nuclear factor kappa B in rats  Document date: 2014_11_10
                    ID: r5hqj5ib_20
                    
                    Snippet: dose-dependent manner. In the groups co-administered 5 or 10 mg/kg BAY11-7082, no ONFH was observed after MPSL treatment. The incidence of ONFH in the group co-administered 5 mg/kg BAY11-7082 was significantly less than that in the Imiquimod þ MPSL group (P ¼ 0.01; Fisher's exact test). However, 1 of 10 rats died within 7 days after the administration of 1, 3, or 5 mg/kg BAY11-7082, and 3 of 6 rats died within 7 days after the administration of.....
                    
                    
                    
                     
                    
                    
                    
                    
                        
                            
                                Document: dose-dependent manner. In the groups co-administered 5 or 10 mg/kg BAY11-7082, no ONFH was observed after MPSL treatment. The incidence of ONFH in the group co-administered 5 mg/kg BAY11-7082 was significantly less than that in the Imiquimod þ MPSL group (P ¼ 0.01; Fisher's exact test). However, 1 of 10 rats died within 7 days after the administration of 1, 3, or 5 mg/kg BAY11-7082, and 3 of 6 rats died within 7 days after the administration of 10 mg/kg BAY11-7082. Owing to the high mortality observed in the BAY11-7082 group, no further experiments were performed using these rats. Figure 4 shows the activity of NF-kB and IRF7 in the liver at 24 h after MPSL treatment in Imiquimod þ MPSL (n ¼ 8)
 
  Search related documents: 
                                Co phrase  search for related documents- dose dependent manner and high mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
  - exact test and Fisher exact test: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76
  - exact test and group onfh incidence: 1
  - exact test and high mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
  - exact test and Imiquimod þ MPSL group: 1
  - exact test and onfh incidence: 1
  - Fisher exact test and high mortality: 1, 2, 3
  - group onfh incidence and Imiquimod þ MPSL group: 1, 2, 3
  - group onfh incidence and MPSL treatment: 1, 2, 3
  - group onfh incidence and onfh incidence: 1, 2, 3, 4, 5, 6
  - Imiquimod þ MPSL group and MPSL treatment: 1, 2, 3
  - Imiquimod þ MPSL group and onfh incidence: 1, 2, 3, 4
  - Imiquimod þ MPSL MPSL treatment and MPSL treatment: 1
  - Imiquimod þ MPSL MPSL treatment and onfh incidence: 1
  - MPSL treatment and onfh incidence: 1, 2, 3, 4, 5, 6, 7
  
 
                                Co phrase  search for related documents, hyperlinks ordered by date